Marshall Wace’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.38M | Buy |
34,793
+22,417
| +181% | +$4.91M | 0.01% | 1106 |
|
|
2026
Q1 | $2.34M | Sell |
12,376
-1,052
| -8% | -$184K | ﹤0.01% | 1698 |
|
|
2025
Q4 | $2.28M | Buy |
+13,428
| New | +$2.06M | ﹤0.01% | 1514 |
|
|
2025
Q3 | – | Sell |
-6,578
| Closed | -$698K | – | 3141 |
|
|
2025
Q2 | $698K | Buy |
+6,578
| New | +$715K | ﹤0.01% | 2011 |
|
|
2025
Q1 | – | Sell |
-59,381
| Closed | -$7.31M | – | 2866 |
|
|
2024
Q4 | $7.31M | Buy |
+59,381
| New | +$7M | 0.01% | 909 |
|
|
2024
Q3 | – | Sell |
-82,959
| Closed | -$8.85M | – | 2742 |
|
|
2024
Q2 | $8.85M | Sell |
82,959
-185,165
| -69% | -$20.4M | 0.01% | 784 |
|
|
2024
Q1 | $32.3M | Buy |
268,124
+238,889
| +817% | +$29.3M | 0.05% | 355 |
|
|
2023
Q4 | $3.6M | Buy |
+29,235
| New | +$3.65M | 0.01% | 1026 |
|
|
2023
Q3 | – | Sell |
-11,153
| Closed | -$1.38M | – | 2449 |
|
|
2023
Q2 | $1.38M | Buy |
+11,153
| New | +$1.5M | ﹤0.01% | 1589 |
|
|
2023
Q1 | – | Sell |
-12,198
| Closed | -$1.94M | – | 2884 |
|
|
2022
Q4 | $1.94M | Buy |
+12,198
| New | +$1.79M | ﹤0.01% | 1756 |
|
|
2021
Q2 | – | Sell |
-17,910
| Closed | -$2.94M | – | 2847 |
|
|
2021
Q1 | $2.94M | Buy |
17,910
+10,391
| +138% | +$1.71M | 0.01% | 1132 |
|
|
2020
Q4 | $1.24M | Buy |
+7,519
| New | +$1.12M | 0.01% | 1128 |
|
|
2020
Q3 | – | Sell |
-39,806
| Closed | -$4.39M | – | 1756 |
|
|
2020
Q2 | $4.39M | Buy |
39,806
+39,654
| +26,088% | +$4.39M | 0.03% | 515 |
|
|
2020
Q1 | $15K | Sell |
152
-252,352
| -100% | -$32.6M | ﹤0.01% | 1532 |
|
|
2019
Q4 | $37.7M | Buy |
252,504
+251,551
| +26,396% | +$34.2M | 0.26% | 91 |
|
|
2019
Q3 | $122K | Buy |
+953
| New | +$128K | ﹤0.01% | 1369 |
|
|
2019
Q2 | – | Sell |
-14,363
| Closed | -$2.05M | – | 1583 |
|
|
2019
Q1 | $2.05M | Buy |
14,363
+1,928
| +16% | +$251K | 0.02% | 728 |
|
|
2018
Q4 | $1.54M | Buy |
+12,435
| New | +$1.84M | 0.02% | 792 |
|
|
2017
Q4 | – | Sell |
-37,944
| Closed | -$5.54M | – | 440 |
|
|
2017
Q3 | $5.54M | Hold |
37,944
| – | – | 0.26% | 86 |
|
|
2017
Q2 | $5.92M | Buy |
37,944
+2,143
| +6% | +$328K | 0.26% | 78 |
|
|
2017
Q1 | $5.19M | Sell |
35,801
-32,686
| -48% | -$4.26M | 0.25% | 87 |
|
|
2016
Q4 | $7.47M | Sell |
68,487
-233,848
| -77% | -$26M | 0.05% | 387 |
|
|
2016
Q3 | $36.7M | Buy |
302,335
+186,998
| +162% | +$25.2M | 0.26% | 94 |
|
|
2016
Q2 | $16.3M | Buy |
+115,337
| New | +$17M | 0.14% | 172 |
|
|
2016
Q1 | – | Sell |
-36,242
| Closed | -$5.09M | – | 1106 |
|
|
2015
Q4 | $5.09M | Buy |
36,242
+3,529
| +11% | +$489K | 0.05% | 373 |
|
|
2015
Q3 | $4.34M | Buy |
32,713
+17,956
| +122% | +$3.09M | 0.05% | 319 |
|
|
2015
Q2 | $2.6M | Buy |
+14,757
| New | +$2.65M | 0.03% | 413 |
|
|
2015
Q1 | – | Sell |
-13,032
| Closed | -$2.13M | – | 865 |
|
|
2014
Q4 | $2.13M | Buy |
13,032
+11,595
| +807% | +$1.92M | 0.03% | 446 |
|
|
2014
Q3 | $231K | Hold |
1,437
| – | – | ﹤0.01% | 751 |
|
|
2014
Q2 | $211K | Sell |
1,437
-863
| -38% | -$120K | ﹤0.01% | 841 |
|
|
2014
Q1 | $319K | Buy |
+2,300
| New | +$346K | 0.01% | 695 |
|
|
2013
Q2 | $206K | Buy |
+3,000
| New | +$183K | 0.01% | 114 |
|
Other funds holding JAZZ
Marshall Wace's JAZZ Position: Q2 2026 in Review
Marshall Wace increased its Jazz Pharmaceuticals (JAZZ) stake by 181% in Q2 2026, buying an estimated $4.91M and bringing the position to 34,793 shares worth $8.38M. The position accounts for 0.01% of the portfolio, ranked #1106.
Marshall Wace first reported a position in JAZZ in Q2 2013 and has held it in 32 quarters since. The position peaked at $37.7M in Q4 2019. 643 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- Marshall Wace held 34,793 shares of Jazz Pharmaceuticals worth $8.38M as of Q2 2026.
- Marshall Wace bought 22,417 Jazz Pharmaceuticals shares in Q2 2026, an estimated $4.91M.
- Jazz Pharmaceuticals made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #1106 holding.
- Marshall Wace first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 32 quarters since.
- Marshall Wace's Jazz Pharmaceuticals position peaked at $37.7M in Q4 2019.
- 643 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.